Midregional pro-Adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study

Potocki, Mihael; Breidthardt, Tobias; Reichlin, Tobias; Morgenthaler, Nils G.; Bergmann, Andreas; Noveanu, Markus; Schaub, Nora; Uthoff, Heiko; Freidank, Heike; Buser, Lorenz; Bingisser, Roland; Christ, Michael; Mebazaa, Alexandre; Müeller, Christian

doi:10.1186/cc7975

Cited by 48 publications

(44 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We screened 422 consecutive patients presenting with suspected CAP from November 2003 to March 2007 for enrolment into this study [8][9][10]. Due to lack of resources, recruitment …”

Section: Methodsmentioning

confidence: 99%

Natriuretic peptides for early prediction of acute kidney injury in community-acquired pneumonia

Nowak

Breidthardt

Dejung

et al. 2013

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

“…We screened 422 consecutive patients presenting with suspected CAP from November 2003 to March 2007 for enrolment into this study [8][9][10]. Due to lack of resources, recruitment …”

Section: Methodsmentioning

confidence: 99%

Natriuretic peptides for early prediction of acute kidney injury in community-acquired pneumonia

Nowak

Breidthardt

Dejung

et al. 2013

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

“…mortality predictor in patients with a variety of underlying diseases presenting to the ED with acute dyspnea [20][21][22][23][24][25][26] and, especially, in patients with CAP [13,[27][28][29][30][31][32][33][34][35][36][37][38]; key studies are summarized in Table 1. Many of the dyspnea and CAP studies [20-23, 25-27, 29-31] had cohorts comprising > 25% of patients with COPD as a cormorbidity.…”

Section: Proadm In the Risk Assessment Of Patients With Other Pulmonamentioning

confidence: 99%

“…There exists a substantial observational literature regarding ProADM use as an all-cause mortality predictor in patients with sepsis [11][12][13][14][15][16][17][18][19], in patients with a variety of underlying diseases presenting to the emergency department (ED) with acute dyspnea [20][21][22][23][24][25][26], and especially in patients with community-acquired pneumonia (CAP) [13,[27][28][29][30][31][32][33][34][35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%

The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review

Schuetz¹,

Marlowe²,

Müeller

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Plasma proadrenomedullin (ProADM) is a blood biomarker that may aid in multidimensional risk assessment of patients with chronic obstructive pulmonary disease (COPD). Co-secreted 1:1 with adrenomedullin (ADM), ProADM is a less biologically active, more chemically stable surrogate for this pluripotent regulatory peptide, which due to biological and ex vivo physical characteristics is difficult to reliably directly quantify. Upregulated by hypoxia, inflammatory cytokines, bacterial products, and shear stress and expressed widely in pulmonary cells and ubiquitously throughout the body, ADM exerts or mediates vasodilatory, natriuretic, diuretic, antioxidative, anti-inflammatory, antimicrobial, and metabolic effects. Observational data from four separate studies totaling 1366 patients suggest that as a single factor, ProADM is a significant independent, and accurate, long-term allcause mortality predictor in COPD. This body of work also suggests that combined with different groups of demographic/clinical variables, ProADM provides significant incremental long-term mortality prediction power relative to the groups of variables alone. Additionally, the literature contains indications that ProADM may be a global cardiopulmonary stress marker, potentially supplying prognostic information when cardiopulmonary exercise testing results such as 6-min walk distance are unavailable due to time or other resource constraints or to a patient's advanced disease. Prospective, randomized, controlled interventional studies are needed to demonstrate whether ProADM use in risk-based guidance of site-of-care, monitoring, and treatment decisions improves clinical, qualityof-life, or pharmacoeconomic outcomes in patients with COPD.

show abstract

“…79 Various comorbidities correlate with MR-proADM, and therefore may harm the diagnostic accuracy of MR-proADM, including age, hypertension, renal failure, coronary artery disease, and diabetes mellitus. 77 As a result, MR-proADM has fallen out of favor as a diagnostic tool.…”

Section: Mid-regional Proadrenomedullinmentioning

confidence: 99%

“…47,77,82 It has been studied with MR-proANP and can perform well as an adjunctive biomarker in this setting. 43,82 Therefore, the current role for MR-proADM is a secondary one as an adjunctive prognostic marker in the setting of ADHF.…”

Section: Mid-regional Proadrenomedullinmentioning

confidence: 99%

Biomarkers in Acute Decompensated Heart Failure

Rosenbaum

Miller

2015

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Acute decompensated heart failure (ADHF) is a prominent condition whose frequency is increasing, especially in the context of an aging population. The ability to discern the cause of undifferentiated dyspnea in acute presentations is an increasing struggle. In this review, we seek to explore the various biomarkers that have been studied for the diagnosis of ADHF and their respective clinical utilities as the most recent data would suggest. Natriuretic peptides, galectin-3, soluble ST2, adrenomedullin, cardiac troponin-T, neutrophil gelatinase-associated lipocalin, and copeptin are reviewed. Of these biomarkers, natriuretic peptides are the most thoroughly evaluated and show the most promise for diagnosis or exclusion of acute heart failure, though other biomarkers can add significant utility in the form of prognostication.KEYWOrDs: acute decompensated heart failure, NT-proBNP, diagnosis, biomarkers CitAtion: rosenbaum and Miller. Biomarkers in acute decompensated heart Failure.

show abstract

Midregional pro-Adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study

Cited by 48 publications

References 47 publications

Natriuretic peptides for early prediction of acute kidney injury in community-acquired pneumonia

Natriuretic peptides for early prediction of acute kidney injury in community-acquired pneumonia

The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review

Biomarkers in Acute Decompensated Heart Failure

Contact Info

Product

Resources

About